middle.news
Prescient Therapeutics Advances PTX-100 Phase 2a Trial, Reduces Loss by 4.4%, Raises $9.8M
9:32am on Friday 21st of August, 2026 AEST
•
Healthcare
Read Story
Prescient Therapeutics Advances PTX-100 Phase 2a Trial, Reduces Loss by 4.4%, Raises $9.8M
9:32am on Friday 21st of August, 2026 AEST
Key Points
Net loss narrowed 4.4% to $7 million
PTX-100 Phase 2a trial expands to 12 active sites internationally
Raised $9.8 million via Share Purchase Plan and placement
European Orphan Drug Designation granted for PTX-100
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE